Lilly's Acquisition of Sigilon Therapeutics Sends Shares Soaring

Eli Lilly and Company has announced its acquisition of Sigilon Therapeutics, a biopharmaceutical company focused on developing functional cures for acute and chronic diseases. The acquisition will enhance Lilly's efforts in developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. The deal involves a tender offer of $14.92 per share in cash, with a potential total consideration of up to $126.56 per share. The transaction is expected to close in the third quarter of 2023.